Dr. Eric Tygenhof

Dr. Eric Tygenhof
Dr. Eric Tygenhof was born and raised in Orange County. He graduated from Stanford University in 2004 and from the University of Southern California Keck School of Medicine in 2009. There he was selected into the prestigious medical honor society Alpha Omega Alpha. He completed his residency at the University of Southern California Institute of Urology, annually recognized as one of the nation’s top training programs. Trained by one of the world’s most honored robotic surgeons, Dr. Tygenhof has a particular interest in robotic kidney-sparing surgery for kidney cancer, robotic prostate removal for cancer, and robotic techniques for benign urologic disease. In addition to minimally-invasive surgery, particularly da Vinci robotics, his training also emphasized urologic prosthetics and reconstruction, female urology, pediatric urology, urologic oncology, and stone disease. Dr. Tygenhof is board-certified, and a member of the American Urologic Association, the Western Section American Urologic Association, the California Urological Association, the Endourological Society, and the Society of Robotic Surgery. His research in the field of urologic prosthetic surgery has been presented at numerous national meetings.
Medical School:

University of Southern California Keck School of Medicine

Residency:

University of Southern California Institute of Urology

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only